308 related articles for article (PubMed ID: 28771058)
1. Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes.
Thota S; Gerds AT
Leuk Lymphoma; 2018 Apr; 59(4):803-812. PubMed ID: 28771058
[TBL] [Abstract][Full Text] [Related]
2. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?
Shallis RM; Zeidan AM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101132. PubMed ID: 32460977
[TBL] [Abstract][Full Text] [Related]
4. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
[TBL] [Abstract][Full Text] [Related]
5. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
6. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
7. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.
Talati C; Padron E
Curr Hematol Malig Rep; 2016 Dec; 11(6):425-433. PubMed ID: 27664113
[TBL] [Abstract][Full Text] [Related]
8.
Montalban-Bravo G; Kanagal-Shamanna R; Sasaki K; Patel K; Ganan-Gomez I; Jabbour E; Kadia T; Ravandi F; DiNardo C; Borthakur G; Takahashi K; Konopleva M; Komrokji RS; DeZern A; Kuzmanovic T; Maciejewski J; Pierce S; Colla S; Sekeres MA; Kantarjian H; Bueso-Ramos C; Garcia-Manero G
Blood Adv; 2019 Mar; 3(6):922-933. PubMed ID: 30902805
[TBL] [Abstract][Full Text] [Related]
9. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
Tiu RV; Sekeres MA
Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
[TBL] [Abstract][Full Text] [Related]
10. Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN).
Smith BN; Savona M; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):1-8. PubMed ID: 30555034
[TBL] [Abstract][Full Text] [Related]
11. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
Patnaik MM; Tefferi A
Am J Hematol; 2021 Mar; 96(3):379-394. PubMed ID: 33428785
[TBL] [Abstract][Full Text] [Related]
13. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic/myeloproliferative neoplasms.
Hyjek E; Vardiman JW
Semin Diagn Pathol; 2011 Nov; 28(4):283-97. PubMed ID: 22195406
[TBL] [Abstract][Full Text] [Related]
15. Many faces of SF3B1-mutated myeloid neoplasms: concurrent mutational profiles contribute to the diverse clinical and morphologic features.
Aqil B; Sukhanova M; Behdad A; Jennings L; Lu X; Chen Q; Chen YH; Gao J
Hum Pathol; 2022 Nov; 129():81-89. PubMed ID: 36087739
[TBL] [Abstract][Full Text] [Related]
16. Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms.
Loghavi S; Wang SA
Surg Pathol Clin; 2019 Sep; 12(3):651-669. PubMed ID: 31352979
[TBL] [Abstract][Full Text] [Related]
17. Pathogenic Mutations and Atypical Flow Cytometric Findings Characterize the Majority of Unclassifiable Myelodysplastic/Myeloproliferative Neoplasms.
Li Y; Beck RC; Moore EM
Am J Clin Pathol; 2021 Sep; 156(4):634-643. PubMed ID: 33877292
[TBL] [Abstract][Full Text] [Related]
18. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.
Zoi K; Cross NC
Int J Hematol; 2015 Mar; 101(3):229-42. PubMed ID: 25212680
[TBL] [Abstract][Full Text] [Related]
20. Myeloproliferative neoplasms (BCR-ABL1 negative) and myelodysplastic/myeloproliferative neoplasms: current diagnostic principles and upcoming updates.
Geyer JT; Orazi A
Int J Lab Hematol; 2016 May; 38 Suppl 1():12-9. PubMed ID: 27161873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
